Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor-fusion protein, for treatment of recurrent/persistent endometrial cancer: GOG-0229N.

Overview

cited authors

Makker, Vicky, Filiaci, Virginia L., Chen, Lee-may, Darus, Christopher, Kendrick, James Erasmus, Sutton, Gregory, Moxley, Katherine, Aghajanian, Carol

authors

Kendrick, James Erasmus IV, MD, FACOG

Publication Date

May 20, 2014

webpage

Web of Science

published in

JOURNAL OF CLINICAL ONCOLOGY Journal

301 E Princeton St., Orlando, FL 32804 | FH.RAS@AdventHealth.com | 407-200-2901

The information on this website is not a substitute for examination, diagnosis, and medical care provided by a licensed and qualified health professional. Please consult your physician before undertaking any form of medical treatment and/or adopting any exercise program or dietary guidelines. If you think you may have a medical emergency, call your physician or 911 immediately. AdventHealth Research Institute reserves the right to add, remove or edit content on this page at its sole discretion.